Browsing Tag
encaleret
3 posts
BridgeBio raises $1bn in preferred equity to fund rare disease product launches
BridgeBio’s $1 billion preferred equity raise strengthens BBIO’s balance sheet as Attruby grows and three rare disease launches approach.
BridgeBio Pharma weighs $1bn KKR, Sixth Street preferred equity deal as launch costs rise
BridgeBio Pharma may be preparing its balance sheet for three potential product launches, but the value of a $1 billion preferred equity deal will depend heavily on its undisclosed dividend, conversion and redemption terms.
How Phase 3 CALIBRATE data reshapes BridgeBio Pharma, Inc.’s rare disease strategy (NASDAQ: BBIO)
Can BridgeBio Pharma, Inc.’s CALIBRATE data turn encaleret into a rare endocrine breakthrough? Explore strategy, risks, and market impact.